Validation of a French screening test for cerebellar cognitive-affective syndrome
Official title: Validation of the Performance of the French Version of the Cerebellar Cognitive-Affective Syndrome Scale (CCASS) as a Screening Test for Cerebellar Cognitive-affective Syndrome: a National Multicenter Study
Run by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace · NCT06005844 · Data updated 2026-11-12
This study is testing a French screening tool to see if it can effectively identify people with cerebellar cognitive-affective syndrome.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 217 (estimated) |
| Sponsor | Groupe Hospitalier de la Region de Mulhouse et Sud Alsace Academic / other |
| Locations | 1 site (Mulhouse, Haut-Rhin) |
| Status | Recruiting |
| Started | November 9, 2023 |
| Main results expected | October 2026 |
| Study ends | March 2027 |
| Registry record updated | May 16, 2025 |
| Trial ID | NCT06005844 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are French-speaking individuals with acquired or degenerative cerebellar pathology.
✕Probably not a fit
Patients with central nervous system pathologies other than cerebellar disease or those with severe sensory impairments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to validate the performance of the French version of the Cerebellar Cognitive-Affective Syndrome Scale (CCASS) as a screening tool for cerebellar cognitive-affective syndrome. It will assess the sensitivity and other accuracy measures of various versions of the CCASS scale through neuropsychological evaluations. The study will be conducted across multiple French centers, where eligible patients will undergo the CCASS test administered by trained neuropsychologists. The results will help determine the effectiveness of the screening tool in identifying patients with this syndrome.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and diagnosis of cerebellar cognitive-affective syndrome, allowing for timely intervention and management.
How similar studies have gone: While this approach is focused on validating a specific screening tool, similar studies have shown success in developing effective diagnostic scales for cognitive disorders.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria : * French speaking * Acquired lesion or predominantly degenerative cerebellar pathology of any etiology * Affiliated or beneficiary of a social security scheme * Written informed consent Non-inclusion criteria: * History or progressive pathology of the central nervous system other than cerebellar disease * Chronic ethylic patient with active consumption, or alcohol withdrawal of less than three months * Use of other toxic substances * Blind or severely visually impaired patient * Deaf or severely hearing-impaired patient unable to understand instructions * Mute patient * Patient deprived of liberty or under legal protection Secondary exclusion criteria : \- Patients with incomplete French scale and/or neuropsychological assessment will be replaced.
Where it's running
-
Ghrmsa
Mulhouse, Haut-Rhin, France Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.